Showing 2621-2630 of 3873 results for "".
- Soliton Takes On Cellulitehttps://modernaesthetics.com/news/soliton-takes-on-cellulite/2471903/
- Galderma's Dysport Celebrates 10 Years Since FDA Approvalhttps://modernaesthetics.com/news/dysport-celebrates-10-years-since-fda-approval/2471921/Galderma Laboratories’ Dysport (abobotulinumtoxinA) is ringing in its 10th birthday. To celebrate this milestone, Galderma is offering double points for Dysport aesthetic treatments registered in
- ASAPS Releases 2019 Plastic Surgery Predictionshttps://modernaesthetics.com/news/asaps-releases-2019-plastic-surgery-predictions/2471968/The coming year will herald less emphasis on celebrity emulation and more emphasis on a tailored, individual look, according to 2019 predictions from
- Alastin Skincare Introduces TransFORM Body Treatment at ASDS Meetinghttps://modernaesthetics.com/news/alastin-skincare-introduces-transform-body-treatment-at-asds-meeting/2472018/
- Evolus Resubmits BLA for DWP-450 Ahead of Schedulehttps://modernaesthetics.com/news/evolus-resubmits-bla-for-dwp-450-ahead-of-schedule/2472049/Evolus has resubmitted its Biologics License Application (BLA) for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the FDA. The resubmission follows the receipt of a Complete Response Letter (“CRL”) from the FDA in May 2018 which necessita
- BTL Geared to Share New Research, Latest Innovation at American Society for Laser Medicine & Surgery Annual Conferencehttps://modernaesthetics.com/news/btl-geared-to-share-new-research-latest-innovation-at-american-society-for-laser-medicine-surgery-annual-conference/2472110/
- AMI Pharm Advances AYP-101 to Phase 3 Testing for Noninflammatory Fat Reductionhttps://modernaesthetics.com/news/ami-pharm-advances-ayp-101-to-phase-3-testing-for-noninflammatory-fat-reduction/2476093/AMI Pharm has initiated a pivotal Phase 3 clinical trial of AYP-101, an investigational injectable for the treatment of submental fat. The study will evaluate the efficacy and safety of the agent, which is designed to reduce localized fat with fewer inflammatory side effects than current therapie
- ProRx Highlights Role of 503B Outsourcing in Patient-Centered Wellness Carehttps://modernaesthetics.com/news/prorx-highlights-role-503b-outsourcing-patient-centered-wellness-care/2476084/In recognition of National Wellness Month, ProRx, an FDA-registered 503B outsourcing facility, is emphasizing the clinical value of personalized, high-quality compounded therapies in wellness-focused care models. ProRx provides sterile and non-sterile compounded medications for office use
- Allergan Aesthetics Announces New ‘Faces of Natrelle’ Campaignhttps://modernaesthetics.com/news/allergan-aesthetics-announces-new-faces-of-natrelle-campaign/2476065/Allergan Aesthetics, an AbbVie company, has introduced “Faces of Natrelle,” a campaign centered on patient narratives surrounding breast augmentation and reconstruction using Natrelle silicone-filled breast implants. The initiative features 9 women selected through a national casting call,
- Obagi Medical Acquires Novaestiq to Introduce HA Injectables in US Markethttps://modernaesthetics.com/news/obagi-medical-acquires-novaestiq-to-introduce-ha-injectables-in-us-market/2475814/Obagi Medical is set to expand into aesthetic injectables following the acquisition of Novaestiq Corp., the company behind the Saypha® ChIQ™ and Saypha® MagIQ™ hyaluronic acid (HA) filler products. The transaction was completed by Obagi’s parent company, Waldencast